Stoke Therapeutics Inc. (NASDAQ: STOK)
$14.73
+0.1500 ( +1.03% ) 548.7K
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
Market Data
Open
$14.73
Previous close
$14.58
Volume
548.7K
Market cap
$768.26M
Day range
$14.56 - $15.25
52 week range
$3.35 - $17.58
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Dec 05, 2023 |
4 | Insider transactions | 1 | Dec 05, 2023 |
4 | Insider transactions | 1 | Dec 05, 2023 |
8-k | 8K-related | 14 | Dec 01, 2023 |
10-q | Quarterly Reports | 60 | Nov 07, 2023 |
8-k | 8K-related | 13 | Nov 07, 2023 |
8-k | 8K-related | 12 | Oct 26, 2023 |
def | Proxies and info statements | 5 | Sep 28, 2023 |
4 | Insider transactions | 1 | Sep 20, 2023 |
3 | Insider transactions | 2 | Sep 20, 2023 |